Background: In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2–neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients with COVID-19 based on an early futility assessment. Objective: To evaluate the a p...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!